← Product Code [JWY](/submissions/MI/subpart-b%E2%80%94diagnostic-devices/JWY) · K062816 # SENSITITRE HAEMOPHILUS/STREPTOCOCCUS PNEUMONIAE (HP) MIC PLATE (K062816) _Trek Diagnostic Systems, Inc. · JWY · Nov 1, 2006 · Microbiology · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/MI/subpart-b%E2%80%94diagnostic-devices/JWY/K062816 ## Device Facts - **Applicant:** Trek Diagnostic Systems, Inc. - **Product Code:** [JWY](/submissions/MI/subpart-b%E2%80%94diagnostic-devices/JWY.md) - **Decision Date:** Nov 1, 2006 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 866.1640 - **Device Class:** Class 2 - **Review Panel:** Microbiology ## Indications for Use The Sensititre® Haemophilus influenzae / Streptococcus pneumoniae (HP) MIC Susceptibility plate is an in vitro diagnostic product for clinical susceptibility testing of Haemophilus influenzae, Streptococcus pneumoniae and Streptococcus species. ## Device Story Sensititre® MIC Susceptibility plates are multi-well microtitre plates containing dried, stabilized antimicrobics; used for quantitative antimicrobial susceptibility testing (AST). Inoculum prepared from colonies via direct method; added to Mueller-Hinton broth with 2–5% lysed horse blood. Plates incubated 20–24 hours in non-CO2 incubator. Growth detected via fluorescence; bacterial surface enzymes cleave fluorogenic substrate, releasing fluorophore. Fluorescence intensity correlates with bacterial growth. MIC determined by lowest antimicrobial concentration inhibiting growth. Readings performed manually or via Sensititre® AutoReader/ARIS® instrumentation. Results assist clinicians in selecting appropriate antibiotic therapy for Streptococcus infections. ## Clinical Evidence No clinical trial data provided. Performance is based on in vitro susceptibility testing data comparing the Sensititre® HP MIC plate results to standard reference methods for the specified Streptococcus species and antimicrobial agents. ## Technological Characteristics Multi-well plastic microtitre plates; dried, stabilized antimicrobics. Fluorescence-based growth detection via enzymatic cleavage of fluorogenic substrate. Energy source: automated reader instrumentation. Dimensions: microtitre plate format. Connectivity: compatible with Sensititre® AutoReader/ARIS®. Software: automated reading algorithm. Sterilization: not specified. ## Regulatory Identification An antimicrobial susceptibility test powder is a device that consists of an antimicrobial drug powder packaged in vials in specified amounts and intended for use in clinical laboratories for determining in vitro susceptibility of bacterial pathogens to these therapeutic agents. Test results are used to determine the antimicrobial agent of choice in the treatment of bacterial diseases. ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0} 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE A. 510(k) Number: k062816 B. Purpose for Submission: To add additional organism groups to the antibiotics meropenem, moxifloxacin, and penicillin on the Sensititre® Haemophilus influenzae / Streptococcus pneumoniae (HP) MIC and Sensititre® Susceptibility Plates C. Measurand: Meropenem Moxifloxacin Penicillin Range µg/mL 0.25 – 2 0.25 – 8 0.03 – 8 D. Type of Test: Quantitative Antimicrobial Susceptibility Test (AST) growth based fluorescence E. Applicant: TREK Diagnostic Systems, Inc. F. Proprietary and Established Names: Sensititre® Haemophilus influenzae / Streptococcus pneumoniae (HP) MIC plates G. Regulatory Information: 1. Regulation section: 866.1640 Antimicrobial Susceptibility Test Powder 2. Classification: II 3. Product code: JWY-manual readings of AST testing of >16 hour incubation LRG Automated readings of AST of >16 hour incubation. 4. Panel: 83 Microbiology H. Intended Use: 1. Intended use(s): The Sensititre® Haemophilus influenzae / Streptococcus pneumoniae (HP) MIC Susceptibility plate is an in vitro diagnostic product for clinical susceptibility {1} testing of Haemophilus influenzae, Streptococcus pneumoniae and Streptococcus species. ## 2. Indication(s) for use: This application is for the addition of Streptococcus species (spp.) to meropenem (0.25 – 2 ug/mL), moxifloxacin (0.25 – 8 ug/mL), and penicillin (0.03 – 8 ug/mL) for use with the Sensititre® Haemophilus influenzae/Streptococcus pneumoniae (HP) MIC Susceptibility Plates. ## 3. Special conditions for use statement(s): For prescription use only ## 4. Special instrument requirements: Automated readings are performed on the Sensititre® AutoReader or Sensititre® ARIS®. ## I. Device Description: Sensititre® MIC Susceptibility plate MIC panels are multi-well plastic microtitre plates, precision dosed with dried, stabilized antimicrobics. This is a microversion of the classic broth dilution methods and can provide both qualitative and quantitative susceptibility results. The medium required for testing S. pneumoniae and Streptococcus spp. is Sensititre® Mueller-Hinton (MH) broth with 2 – 5% lysed horse blood with a final organism density of 5 X 10⁵ colony units (CFU/mL). This is then incubated in a non CO₂ incubator for 20 – 24 hour and read manually for growth or using the Sensititre® autoread. ## J. Substantial Equivalence Information: 1. Predicate device name(s): Pasco MIC and MIC/ID Panels 2. Predicate 510(k) number(s): K033119 3. Comparison with predicate: | Similarities | | | | --- | --- | --- | | Item | Device | Predicate | | Intended use | an in vitro diagnostic product for clinical susceptibility testing of gram negative and gram positive organisms. | Same | | Inoculum | Prepared from colonies using the direct inoculation method | Same | {2} | Similarities | | | | --- | --- | --- | | Item | Device | Predicate | | Growth medium | Mueller – Hinton (MH) broth with 2 – 5% lysed horse blood | Same | | Inoculation method | Direct equated to a 0.5 McFarland | Same | | Differences | | | | Item | Device | Predicate | | Type panel | Dried antibiotics | 100 μl/well frozen | | Incubation | 20 - 24 hours | 16-24 hours | | Technology | Fluorescence detection of growth | Turbidity detection of growth | | Reading method | Visual growth and Auto read by instrumentation | Turbidity detection of growth | K. Standard/Guidance Document Referenced (if applicable): “Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test Systems; Guidance for Industry and FDA”; CLSI M7 (M100-S16) “Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard.” L. Test Principle: The Sensititre® Autoread System utilizes fluorescence technology to read 24 hour Streptococcus pneumoniae and Streptococcus spp. plates. The technology involves the detection of bacterial growth by monitoring the activity of specific surface enzymes produced by the test organism. Growth is determined by generating a fluorescent product from a non-fluorescent (fluorogenic) substrate. The non-fluorescent substrate is prepared by conjugating a fluorescent compound to the specific enzyme substrates with a bond, which prevents fluorescence. The fluorophore, is then said to be quenched. The substrate is added to the inoculum broth and dispensed into the test plates at the same time as the test organism or the plates can be prepared with the substrate already added to the plate. Enzymatic action of the bacterial surface enzymes on the specific substrates, cleave this bond releasing the fluorophore, which is now capable of fluorescence. The amount of fluorescence detected is directly related to the activity of bacterial growth. The MIC is determined by observing the lowest dilution of antimicrobial agent that inhibits growth of the organism or automatically for the detection of fluorescence. M. Performance Characteristics (if/when applicable): 1. Analytical performance: a. Precision/Reproducibility: A reproducibility study was performed on 25 Streptococcus spp. These isolates were tested once for each antimicrobial at each of the three sites on {3} the automated and manual read methods demonstrating >95% reproducibility for both read methods. b. Linearity/assay reportable range: Not applicable c. Traceability, Stability, Expected values (controls, calibrators, or methods): The recommended QC isolate, S. pneumoniae 49619 was tested daily with acceptable results. Quality control was also performed at all sites using both manual and autoread methods. The Sensititre® results demonstrated that the system can produce QC results in the recommended range for both manual and automated read methods. The mode is the same between the reference method and the two read methods. An additional QC organism S. pneumoniae #5 was tested to provide on-scale results. The reference method was in range for every day tested. Quality Control Table | Antimicrobial | ORGANISM | Conc ug/mL | Sensititre® Autoread | Sensititre® manual | Reference | | --- | --- | --- | --- | --- | --- | | | | | | | | | Meropenem | S. pneumoniae ATCC 49619 Exp. Range: 0.06 – 0.25 ug/ml | ≤0.25 | 60 | 60 | 60 | | | | | | | | | | S. pneumoniae #5 Exp. Range: 0.5 – 2 ug/ml | 0.5 | 58 | 53 | 43 | | | | 1 | 2 | 7 | 17 | | | | | | | | | Moxifloxacin | S. pneumoniae ATCC 49619 Exp. Range: 0.06 – 0.25 μg/mL | ≤0.25 | 60 | 60 | 60 | | | | | | | | | | S. pneumoniae #5 Exp. Range: 0.06 – 0.25 μg/mL | ≤0.25 | 60 | 60 | 60 | | | | | | | | | | | | | | | | Penicillin | S. pneumoniae ATCC 49619 Exp. Range: 0.25 – 1 ug/ml | 0.25 | 23 | 15 | 14 | | | | 0.5 | 37 | 45 | 46 | | | S. pneumoniae #5 Exp. Range: >1 μg/mL | 2 | 38 | 36 | 42 | | | | 4 | 22 | 24 | 18 | | | | | | | | Nephelometer was used at each site to standardize the inoculum and it was calibrated each time it was switched on. Colony counts from QC ATCC and in-house source was performed using direct inoculum method and the mean result was within the minimum and maximum ranges. d. Detection limit: Not Applicable e. Analytical specificity: Not Applicable {4} f. Assay cut-off: Not Applicable 2. Comparison studies: a. Method comparison with predicate device: The recommended broth dilution reference panel was prepared according to the CLSI recommendation. Clinical testing included both fresh and stock clinical isolates and a set of challenge organisms. The broth reference panel for Streptococcus spp. was set up on MH supplemented with 2% to 5% lysed horse blood as recommended by CLSI and incubated in a non CO2 incubator for 20 – 24 hours. The comparison resulted in the following performance evaluations as reflected below. Summary Table for Streptococcus spp. Other than S. pneumoniae (Manual Read Method) | | EA Tot | EA N | EA % | Eval EA Tot | Eval EA N | Eval EA % | CA N | CA % | #NS/ R | min | maj | vmj | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | *Meropenem | 349 | 349 | 100 | 15 | 15 | 100 | 349 | 100 | 0 | 0 | 0 | 0 | | Moxifloxacin | 349 | 349 | 100 | 4 | 4 | 100 | 349 | 100 | 0 | 0 | 0 | 0 | | Penicillin | 349 | 348 | 99.7 | 154 | 154 | 100 | 346 | 99.1 | 17 | 3 | 0 | 0 | EA-Essential Agreement vmj – very major discrepancies CA-Category Agreement maj – major discrepancies R-resistant isolates min – minor discrepancies *NS-Not susceptible, only susceptible category exists Summary Table for Streptococcus spp. Other than S. pneumoniae (AutoRead Method) | | EA Tot | EA N | EA % | Eval EA Tot | Eval EA N | Eval EA % | CA N | CA % | #NS/ R | min | maj | vmj | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | *Meropenem | 349 | 349 | 100 | 16 | 16 | 100 | 349 | 100 | 0 | 0 | 0 | 0 | | Moxifloxacin | 349 | 349 | 100 | 4 | 4 | 100 | 349 | 100 | 0 | 0 | 0 | 0 | | Penicillin | 349 | 344 | 98.6 | 165 | 163 | 98.8 | 342 | 98.0 | 17 | 7 | 0 | 0 | EA-Essential Agreement vmj – very major discrepancies CA-Category Agreement maj – major discrepancies R-resistant isolates min – minor discrepancies *NS-Not susceptible, only susceptible category exists EA is when there is agreement between the reference method and the Sensititre® panel within plus or minus one serial two-fold dilution of antibiotic. Category agreement (CA) is when the Sensititre® panel interpretative results, Sensitive, Intermediate, and Resistant (SIR) agrees exactly with the reference panel result interpretation. Evaluable EA is when the MIC result is on scale for both the Sensititre® and the reference and have on-scale EA. The EA% is acceptable when compared to the reference method as described in the FDA guidance document, "Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA". {5} The charts above demonstrated that the performance for Streptococcus spp. other than S. pneumoniae was acceptable for both methods of reading. The growth rate for Streptococcus spp. is greater than 90%. b. Matrix comparison: Not Applicable 3. Clinical studies: a. Clinical Sensitivity: Not Applicable b. Clinical specificity: Not Applicable c. Other clinical supportive data (when a. and b. are not applicable): Not Applicable 4. Clinical cut-off: Not Applicable 5. Expected values/Reference range: | Antibiotic | Organism | Interpretative Criteria | | --- | --- | --- | | *Meropenem* | *Streptococcus* spp. other than S. pneumoniae | ≤0.5 (S) | | *Moxifloxacin* | *Streptococcus* spp. including S. pneumoniae | ≤1 (S), 2 (I), ≥4 (R) | | *Penicillin* | **Streptococcus* spp. other than S. pneumoniae (beta-hemolytic group) | ≤0.12 (S) | | | *Streptococcus* spp. other than S. pneumoniae (Viridans group) | ≤0.12 (S), 0.25 – 2 (I), ≥4 (R) | a(CLSI Comment) For some organism/antimicrobial agent combinations, the absence or rare occurrence of resistant strains precludes defining any results categories other than "susceptible." For strains yielding results suggestive of a "nonsusceptible" category, organism identification and antimicrobial susceptibility test results should be confirmed. Subsequently, the isolates should be saved and submitted to a reference laboratory that will confirm results using a CLSI/NCCLS reference dilution method. b(FDA Comment) This interpretive standard is applicable only to broth microdilution susceptibility tests using cation-adjusted Mueller-Hinton broth with 2 – 5% lysed horse blood. {6} *(CLSI Comment) Strains of beta-hemolytic streptococci with penicillin MICs of greater than 0.12 µg/mL or ampicillin MICs of greater than 0.25 µg/mL have not been observed; submit such strains to a reference laboratory. N. Proposed Labeling: The expected value range, interpretive criteria and QC for gram positive panels are included in the package insert. The labeling is sufficient and satisfies the requirements of 21 CFR Part 809.10. O. Conclusion: The submitted information in this premarket notification is complete and supports a substantial equivalence decision. 7 --- **Source:** [https://fda.innolitics.com/submissions/MI/subpart-b%E2%80%94diagnostic-devices/JWY/K062816](https://fda.innolitics.com/submissions/MI/subpart-b%E2%80%94diagnostic-devices/JWY/K062816) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com